| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, DC 20549 |
| |
| |
| FORM 8-K |
| CURRENT REPORT Pursuant |
| to Section 13 or 15(d) of the |
| Securities Exchange Act of 1934 |
| |
| Date of report (Date of earliest event reported):March 29, 2016 |
Bionik Laboratories Corp. |
| (Exact Name of Registrant as Specified in Its Charter) |
| Delaware | | 000-54717 | | 27-1340346 |
| (State or Other Jurisdiction of Incorporation or Organization) | | (Commission File Number) | | (IRS Employer Identification No.) |
483 Bay Street, N105 Toronto, ON | | M5G 2C9 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (416) 640-7887 |
| |
|
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
A copy of material that will be used in investor presentations, which are scheduled to begin the week of March 28, 2016, and delivered by the management and representatives of Bionik Laboratories Corp. (the “Registrant”) from time to time, is attached to this Current Report on Form 8-K as Exhibit 99.1. These materials are dated as of March 29, 2016, and the Registrant disclaims any obligation to correct or update these materials in the future, except as required by law.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Investor Presentation dated March 29, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: March 29, 2016
| | BIONIK LABORATORIES CORP. |
| | | |
| | By: | /s/Peter Bloch |
| | Name: | Peter Bloch |
| | Title: | Chief Executive Officer |
